View Document Preview and Link Document Date: 2014-11-06 23:49:33 Open Document File Size: 70,22 KB Share Result on Facebook
Company Roche Diagnostics Australia Pty Limited / Roche Diagnostic Australia Pty Limited / Roche Products Pty Limited / BRAF / Roche Diagnostics Pty Ltd / PBAC / MSAC / / Currency USD / / Event Product Issues / FDA Phase / / Facility Authority (NATA)/Royal College of Pathologists / / IndustryTerm health services / clinical management / treatment of melanoma / agreed clinical protocols / health technology assessments / / MedicalCondition BRAF V600E-mutated melanomas / metastasis / non-V600E Mutation Positive Disease / thrombocytopenia / sun-exposed melanoma / cutaneous metastatic melanomas / melanoma / metastatic non-small cell lung cancer / IV cutaneous melanoma / breast cancer / IV (metastatic) melanoma / IV metastatic cutaneous melanoma / IV metastatic melanoma / IV melanoma / progressive disease / tumour / Australian melanoma / BRAF V600 positive melanoma / cutaneous cutaneous squamous cell carcinoma / tumours / metastatic melanoma / / MedicalTreatment chemotherapy / clinical protocols / platelet transfusion / / Organization National Association / World Health Organization / Therapeutic Goods Administration / Medicare / College of Pathologists of Australasia / Pathology Services Advisory Committee / Department of Health / Australian Health Ministers’ Advisory Council / / Position Minister / consultant physician / Governor / pathologist / Executive / / Product V600E / dacarbazine / amount / V600 / / Technology diagnostic tests / agreed clinical protocols / chemotherapy / / URL www.msac.gov.au / / SocialTag 
Public Summary Document Application No. 1172 – BRAF genetic testing in patients with melanoma for access to proposed PBS-funded vemurafenib Sponsor/Applicant/s: Roche Diagnostic Australia Pty Limited and